Eric Lefkofsky – Changing The Way We Treat Cancer
Statistics show that forty percent of adults in the United States will face cancer at some point in their adult life. These statistics show that cancer touches everyone personally or through someone they know at some point. The National Cancer Institute, estimated that in 2014 nearly 14.5 million people in the U.S. were living with cancer. It is projected that this number will jump to over 19 million by the year 2024.
People like Eric Lefkofsky and his company Tempus are looking to change these projections. Tempus is taking the lead in the innovative field of data-enabled precision medicine. Technology is advancing all around us and one would assume it is advancing in the medical field as well. But when it comes to data collection and digital technology, there was something missing. Eric Lefkofsky learned this first hand when his wife was diagnosed with breast cancer and he set out to do something about it.
As a firm Tempus, had a goal of changing the way cancer care was being delivered. Their platform has been created to analyze a patients clinical and molecular data. There were several hurdles Tempus had to overcome in developing this technology. One being the expense of information. Since the future of fighting cancer seems to be directed at treating it on the molecular level, Tempus has tried to combine information in order to provide the effective cancer treatments.
Eric Lefkofsky, currently resides in Chicago where Tempus is headquartered. He serves as a member of the board of directors for Lurie’s Children Memorial Hospital of Chicago and is on the board of trustees for The Steppenworth Theatre of Chicago. Eric still hasn’t reached the age of 50 and is very accomplished. He graduated from the University of Michigan in Ann Arbor. He earned his Juris Doctor from the University of Michigan Law School. Despite his education he never became a lawyer, instead he found himself involved in the dot-com movement and very successful at it. He has held a number of teaching positions and is currently an adjunt professor at the University of Chicago’s Booth School of Business.